With over 0.48 million ASLAN Pharmaceuticals Ltd ADR (ASLN) shares trading Friday and a closing price of $0.40 on the day, the dollar volume was approximately $0.19 million. The shares have shown a negative half year performance of -89.47% and its price on 12/22/23 lost nearly -11.99%. Currently, there are 16.67M common shares owned by the public and among those 16.09M shares have been available to trade.
Fidelity Nasdaq Composite Index F owns 7968.0 shares of the company’s stock, all valued at over $5498.0.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Shares of ASLAN Pharmaceuticals Ltd ADR (NASDAQ: ASLN) opened at $0.44, down -$0.02 from a prior closing price of $0.46. However, the script later moved the day high at 0.4897, down -11.99%. The company’s stock has a 5-day price change of -30.42% and -78.38% over the past three months. ASLN shares are trading -77.66% year to date (YTD), with the 12-month market performance down to -80.41% lower. It has a 12-month low price of $0.43 and touched a high of $4.69 over the same period. ASLN has an average intraday trading volume of 93.94K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -28.09%, -55.60%, and -83.60% respectively.
Institutional ownership of ASLAN Pharmaceuticals Ltd ADR (NASDAQ: ASLN) shares accounts for 30.55% of the company’s 16.67M shares outstanding. Mutual fund holders own –, while other institutional holders and individual stakeholders account for — and — respectively.
It has a market capitalization of $6.70M and a beta (3y monthly) value of 1.36. The earnings-per-share (ttm) stands at -$3.01. Price movements for the stock have been influenced by the stock’s volatility, which stands at 18.79% over the week and 13.97% over the month.
Analysts forecast that ASLAN Pharmaceuticals Ltd ADR (ASLN) will achieve an EPS of -$0.65 for the current quarter, -$0.63 for the next quarter and -$4.25 for 2024. The lowest estimate earnings-per-share for the quarter is -$0.65 while analysts give the company a high EPS estimate of -$0.65. Comparatively, EPS for the current quarter was -$1.04 a year ago. Earnings per share for the fiscal year are expected to increase by 26.22%, and -34.99% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 3 brokerage firm advisors rate ASLAN Pharmaceuticals Ltd ADR (ASLN) as a “Strong Buy” at a consensus score of 1.00. Specifically, 3 Wall Street analysts polled rate the stock as a buy, while 0 of the 3 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the ASLN, a number of firms have released research notes about the stock. Jefferies stated their Buy rating for the stock in a research note on July 09, 2021, with the firm’s price target at $8.
